Most Recent Articles by Leah Lawrence
Atezolizumab is the most recent in a line of immune checkpoint inhibitors approved for patients with NSCLC.
Recent research is inconsistent about whether turmeric supplements can prevent and treat cancer.
Cancer Therapy Advisor interviewed Dr Bakal about this new approach to analyzing cell shape and its potential to affect breast cancer treatment.
At an education session at the 2017 GU Symposium experts will discuss some of the barriers to progress in the treatment of bladder cancer.
Genetic factors underlying colorectal cancer (CRC) development may extend beyond those patients with well-known, high-risk features.
More Articles by Leah Lawrence
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Low-fat Diet and Breast Cancer
- The Adverse Effects of Sarcoma Treatment in Cancer Survivors
- Some Patients With Terminal Cancer Receive Unnecessary Aggressive Treatment
- Anti-CD19 CAR-T Cells May Be Safe and Effective in Chronic Lymphocytic Leukemia
- Active Surveillance and Watchful Waiting for Low-risk Prostate Cancer
- Weight in Adolescence May Predict Colorectal Cancer Risk
- Haploidentical Transplantation Effective as Front-line Therapy for Standard-risk ALL
- Ipilimumab Indication Expanded To Include Pediatric Unresectable or Metastatic Melanoma
- Immune-mediated Hepatitis: Challenges in Management
- Phase 1 Study of A Dendritic Cell Vaccine for High-grade Glioma and Glioblastoma